Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Jawad Francis"'
Autor:
Shanta Chawla, Manuel Modiano, Jayaram S. Bharadwaj, Jawad Francis, Hlalah Osama, Lee S. Schwartzberg, Nishan Tchekmedyian, Francois Lebel, Gajanan Bhat
Publikováno v:
Blood. 136:34-35
Background: Eflapegrastim (Rolontis®, Efla) is a long-acting granulocyte-colony stimulating factor (G-CSF), consisting of a recombinant human G-CSF analog conjugated to a human IgG4 Fc fragment via a short polyethylene glycol linker. Efla is not a b
Autor:
Manuel Modiano, Shanta Chawla, Jayaram S. Bharadwaj, Jawad Francis, Lee S. Schwartzberg, Francois Lebel, Gajanan Bhat, Hlalah Osama, Nishan Tchekmedyian
Publikováno v:
Cancer Research. 81:OT-06
Background: Eflapegrastim (Rolontis®, Efla) is a long-acting granulocyte-colony stimulating factor (G-CSF), consisting of a recombinant human G-CSF analog conjugated to a human IgG4 Fc fragment via a short polyethylene glycol linker. Efla is not a b
Autor:
Lancelot McLean, Eileen Brantley, Ubaldo Soto, Yves Pommier, Keli Agama, Lawrence C. Sowers, Randi Jimenez, Jawad Francis
Publikováno v:
International Journal of Cancer. 122:1665-1674
Aminoflavone (5-amino-2-(4-amino-3-fluorophenyl)-6,8-difluoro-7-methylchromen-4-one; AF; NSC 686288), a novel anticancer candidate agent, is undergoing clinical evaluation. AF induces DNA-protein cross-links (DPCs), Gamma-H2AX phosphorylation, aryl h
Autor:
James E. Thompson, Eunice S. Wang, Jawad Francis, Avinash V. Dharmadhikari, Meir Wetzler, Paul K. Wallace, George Deeb, Sheila N.J. Sait
Aberrant expression of the B lymphoid marker, CD19, in acute myeloid leukemia (AML) has frequently been associated with t(8;21)(q22;q22). However, AML cases lacking t(8;21) may occasionally express CD19. We asked whether CD19 expression is restricted
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b3a5b148c78152d170ac2ed37f2d6c9
https://europepmc.org/articles/PMC6668030/
https://europepmc.org/articles/PMC6668030/
Publikováno v:
Leukemia Research. 35:e35-e36
Approximately 10–20% of myelodysplastic syndromes (MDS) are associated with an autoimmune disease (AID) (1) and recent data suggest T-cell abnormalities are involved in both diseases’ pathology (2, 3). We therefore asked whether treating the MDS
Autor:
Paul K. Wallace, Eunice S. Wang, George Deeb, Sheila N.J. Sait, Avinash Dharmadhikari, Meir Wetzler, James E. Thompson, Jawad Francis
Publikováno v:
Blood. 114:4128-4128
Abstract 4128 Aberrant expression of the B lymphoid marker, CD19, in acute myeloid leukemia (AML) has frequently been associated with t(8;21)(q22;q22). However, AML cases lacking this translocation may occasionally express CD19. We identified eight s